title: Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis.
abstract: OBJECTIVE
  To measure the levels of Tumor necrosis factor (TNF)-like ligand 1A (TL1A) and decoy receptor 3 (DcR3) in serum and synovial fluid (SF) of patients with rheumatoid arthritis (RA). To evaluate the effect of recombinant human (rh) TL1A on interleukin (IL)-17 production and IL-17mRNA expression.
  
  
  METHODS
  The serum and SF levels of TL1A and DcR3, and the production of IL-17 by rhTL1A-treated PBMC were measured by enzyme-linked immunosorbent assay (ELISA). The expression of IL-17 mRNA by rhTL1A-treated PBMC was measured by real-time reverse transcriptase polymerase chain reaction (RT-PCR). We also tested the change of TL1A and DcR3 level following TNF-α blockade therapy.
  
  
  RESULTS
  Serum TL1A and DcR3 levels were higher in RA patients. This increase was more significant in RF and anti-CCP positive patients. TL1A and DcR3 levels were higher in SF samples than in paired sera. TL1A and DcR3 decreased after anti-TNF treatment. rhTL1A increased the production of IL-17 protein and the expression of IL-17mRNA.
  
  
  CONCLUSIONS
  TL1A and DcR3 may be of pathogenic and potentially of therapeutic importance in RA patients.
authors: Department of Rheumatology, 1st Affiliated Hospital of China Medical University, Shen Yang 110001, China.
authors: Zijuan
authors: Z
authors: Xiu
authors: Department of Rheumatology, 1st Affiliated Hospital of China Medical University, Shen Yang 110001, China. Electronic address: shenhuicam@sohu.com.
authors: Hui
authors: H
authors: Shen
authors: Department of Rheumatology, 1st Affiliated Hospital of China Medical University, Shen Yang 110001, China.
authors: Ye
authors: Y
authors: Tian
authors: Department of Rheumatology, 1st Affiliated Hospital of China Medical University, Shen Yang 110001, China.
authors: Liping
authors: L
authors: Xia
authors: Department of Rheumatology, 1st Affiliated Hospital of China Medical University, Shen Yang 110001, China.
authors: Jing
authors: J
authors: Lu
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001172:Arthritis, Rheumatoid / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000008:administration & dosage / Q000627:therapeutic use; D020381:Interleukin-17 / Q000235:genetics / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D060888:Real-Time Polymerase Chain Reaction; D053323:Receptors, Tumor Necrosis Factor, Member 6b / Q000097:blood / Q000378:metabolism*; D013582:Synovial Fluid / Q000276:immunology*; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15 / Q000097:blood / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D020381:Interleukin-17; D053323:Receptors, Tumor Necrosis Factor, Member 6b; C505911:TNFRSF6B protein, human; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Decoy receptor 3; Interleukin-17; Rheumatoid arthritis; Tumor necrosis factor-like ligand 1A